CD44v6 is highly expressed in many cancers, and acts as co−receptor for at least three receptor tyrosine kinases (c−Met [26,27], EGFR [28], and VEGFR−2 [29]), which contribute to the oncogenic functions of CD44v6. This evidence concerns the gene MET and cancer.